Lymphotoxin-alpha-based therapy

About Cycuria Therapeutics

Cycuria Therapeutics is a private, preclinical-stage biotech based in Graz, Austria, developing engineered biologic therapies for hard-to-treat cancers, with an initial focus on acute myeloid leukemia (AML). The company's proprietary platform aims to create first-in-class therapies that specifically eradicate leukemic stem cells, a key driver of relapse, while minimizing toxicity to healthy hematopoiesis. Led by a team with expertise in protein engineering and hemato-oncology, Cycuria is advancing a novel approach based on lymphotoxin-alpha biology, as evidenced by recent promising preclinical publications. The company is positioned to address a large market with high unmet need, particularly in older AML patients who cannot tolerate intensive standard therapies.

Therapeutic Areas

Other Acute Myeloid Leukemia (AML) Drugs